Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 18/20 | 0.74 |
| ▸ | BCR | P11274 | 11/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12852079 | 0.91 | ABL1 (0.64) | ABL1BCR | |
| SCHEMBL17074675 | 0.89 | ABL1 (0.71) | ABL1BCRSRC | |
| SCHEMBL4121584 | 0.89 | ABL1 (0.73) | ABL1BCR | |
| SCHEMBL12852047 | 0.88 | ABL1 (0.75) | ABL1BCR | |
| SCHEMBL12852057 | 0.87 | ABL1 (0.65) | ABL1BCRSRC | |
| SCHEMBL12851991 | 0.87 | ABL1 (0.75) | ABL1BCRSRCNR2E1 | |
| SCHEMBL13813501 | 0.85 | ABL1 (0.61) | ABL1BCRSRCNR2E1 | |
| SCHEMBL3428132 | 0.85 | ABL1 (1.00) | ABL1BCRSRCNR2E1 | |
| SCHEMBL29515144 | 0.85 | ABL1 (1.00) | ABL1BCRSRCNR2E1 | |
| SCHEMBL15511376 | 0.84 | ABL1 (0.77) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024366-B1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2015-09-16 | — | — | EP | claimed |
| US-8278307-B2 | Monocyclic Heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | claimed |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| EP-2024366-B1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2024366-B1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8278307-B2 | Monocyclic Heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278307-B2 | Monocyclic Heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | ABL1 357/4885BCR 1073/4885SRC 3503/4885 |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | CYP3A43, CYP2F1, CYP11B2 | ABL1 71/4885BCR 452/4885SRC 2229/4885 |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | CYP3A43, CYP2F1, CYP11B2 | ABL1 71/4885BCR 452/4885SRC 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.